1171 related articles for article (PubMed ID: 15370367)
1. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
[TBL] [Abstract][Full Text] [Related]
2. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPbetaCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies.
Wang S; Li D; Ito Y; Liu X; Zhang J; Wu C
J Pharm Pharmacol; 2004 Oct; 56(10):1251-7. PubMed ID: 15482639
[TBL] [Abstract][Full Text] [Related]
3. Delay in ICR/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-beta-cyclodextrin inclusion complex.
Nagai N; Takeda M; Ito Y; Takeuchi N; Kamei A
Biol Pharm Bull; 2007 Aug; 30(8):1529-34. PubMed ID: 17666815
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.
Kristinsson JK; Fridriksdóttir H; Thórisdóttir S; Sigurdardóttir AM; Stefánsson E; Loftsson T
Invest Ophthalmol Vis Sci; 1996 May; 37(6):1199-203. PubMed ID: 8631635
[TBL] [Abstract][Full Text] [Related]
5. Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models.
Nagai N; Yoshioka C; Mano Y; Ito Y; Okamoto N; Shimomura Y
Curr Eye Res; 2015; 40(10):990-1000. PubMed ID: 25330366
[TBL] [Abstract][Full Text] [Related]
6. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure.
Nagai N; Yoshioka C; Mano Y; Tnabe W; Ito Y; Okamoto N; Shimomura Y
Exp Eye Res; 2015 Mar; 132():115-23. PubMed ID: 25633346
[TBL] [Abstract][Full Text] [Related]
7. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit.
Ito Y; Nagai N; Shimomura Y
Biol Pharm Bull; 2010; 33(9):1574-8. PubMed ID: 20823577
[TBL] [Abstract][Full Text] [Related]
8. Effects of instillation of eyedrops containing disulfiram and hydroxypropyl-β-cyclodextrin inclusion complex on endotoxin-induced uveitis in rats.
Kanai K; Ito Y; Nagai N; Itoh N; Hori Y; Chikazawa S; Hoshi F; Higuchi S
Curr Eye Res; 2012 Feb; 37(2):124-31. PubMed ID: 22029776
[TBL] [Abstract][Full Text] [Related]
9. Octa-arginine modified lipid emulsions as a potential ocular delivery system for disulfiram: A study of the corneal permeation, transcorneal mechanism and anti-cataract effect.
Liu C; Lan Q; He W; Nie C; Zhang C; Xu T; Jiang T; Wang S
Colloids Surf B Biointerfaces; 2017 Dec; 160():305-314. PubMed ID: 28950195
[TBL] [Abstract][Full Text] [Related]
10. Correlation between prevention of cataract development by disulfiram and fates of selenium in selenite-treated rats.
Ito Y; Cai H; Koizumi Y; Nakao M; Terao M
Curr Eye Res; 1999 Apr; 18(4):292-9. PubMed ID: 10372989
[TBL] [Abstract][Full Text] [Related]
11. Ocular pharmacokinetics and availability of topically applied baicalein in rabbits.
Zhang L; Zhang J; Wang L; Xia H
Curr Eye Res; 2009 Apr; 34(4):257-63. PubMed ID: 19373573
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model.
Nagai N; Ito Y; Takeuchi N
Biol Pharm Bull; 2012; 35(2):239-45. PubMed ID: 22293355
[TBL] [Abstract][Full Text] [Related]
13. Effects of lipid composition on the transcorneal penetration of liposomes containing disulfiram, a potential anti-cataract agent, in the rabbit.
Ito Y; Cai H; Koizumi Y; Hori R; Terao M; Kimura T; Takagi S; Tomohiro M
Biol Pharm Bull; 2000 Mar; 23(3):327-33. PubMed ID: 10726888
[TBL] [Abstract][Full Text] [Related]
14. An Ophthalmic Formulation of Disulfiram Nanoparticles Prolongs Drug Residence Time in Lens.
Nagai N; Mano Y; Ito Y
Biol Pharm Bull; 2016; 39(11):1881-1887. PubMed ID: 27803460
[TBL] [Abstract][Full Text] [Related]
15. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits.
Zhang J; Wang L; Gao C; Zhang L; Xia H
J Ocul Pharmacol Ther; 2008 Oct; 24(5):501-6. PubMed ID: 18803444
[TBL] [Abstract][Full Text] [Related]
16. [Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops].
Zhang JJ; Gao CF; Wang LY
Zhonghua Yan Ke Za Zhi; 2006 Jul; 42(7):637-41. PubMed ID: 17081425
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydroxypropyl-β-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel.
Kesavan K; Kant S; Singh PN; Pandit JK
Curr Eye Res; 2011 Oct; 36(10):918-29. PubMed ID: 21950697
[TBL] [Abstract][Full Text] [Related]
18. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
Kador PF; Randazzo J; Babb T; Koushik K; Takamura Y; Zhu W; Blessing K; Kompella UB
J Ocul Pharmacol Ther; 2007 Apr; 23(2):116-23. PubMed ID: 17444799
[TBL] [Abstract][Full Text] [Related]
19. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
Loftsson T; Hreinsdóttir D; Stefánsson E
J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
